The future of antibody-drug conjugates in urothelial cancer [Video]

Findings from the Phase III EV-302 trial (NCT04223856) of enfortumab vedotin, an antibody-drug conjugate (ADC), and pembrolizumab in patients with locally advanced or metastatic urothelial cancer have been practice changing in the first-line setting. Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the future of the ADCs in urothelial carcinoma. Additional research is required to reduce toxicity and elucidate novel biomarkers. Numerous trials are also underway assessing enfortumab vedotin in the neoadjuvant setting, as well as other ADCs such as sacituzumab govitecan and disitamab vedotin. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.